

An Efficient Synthesis of Aryl Phenacetates Using Acid Catalyzed Dicyclohexylcarbodiimide Esterification and Transient *N*-*tert*-Butoxycarbonylation


Daniel Cabaret, Jie Liu, Michel Wakselman*

CNRS-CERCOA, 2 rue Henri Dunant, F-94320 Thiais, France

Received 8 October 1993; revised 6 December 1993

Application of the Holmberg procedure (DCC/pyridine/*p*-TSA_{cat}) improves the yield of the direct condensation of phenols with phenylacetyl glycine (**1**). Moreover, *N*-*tert*-butoxycarbonylation of **1** impedes an intramolecular reaction leading to an oxazolone, and allows the formation of stable aryl *N*-Boc phenacetates. Then, mild cleavage of the Boc group with four equivalents of trifluoroacetic acid furnishes the aryl phenylacetyl glycinate. This indirect method is more efficient than its direct analog in the case of phenols possessing electron-withdrawing substituents.

For an ongoing project concerning the study of new β -lactamase substrates and inhibitors, an efficient synthesis of phenylacetyl glycine aryl esters (aryl phenacetates) was needed.¹ Phenyl and *p*-alkoxycarbonylphenyl phenacetates are formed in aqueous solutions of potassium penicillin G which contain phenols as preservatives.^{2,3} They have been synthesized in about 20 % yield by heating a mixture of a phenol and the 2-benzyl-5-(4*H*)-oxazolone hydrobromide (**2**, HBr) obtained by treatment of phenaceturic acid (**1**) with phosphorous tribromide.^{2,3} *ortho*-, *meta*- and *para*-Benzyloxycarbonylphenyl phenacetates have also been prepared from the acid **1** and the corresponding benzyl hydroxybenzoate using 1,1'-carbonyldiimidazole as the activating agent.⁴ Activated derivatives of hippurates (*N*-benzoylglycinates) and other *N*-acylglycine analogs,⁵ such as **1**, are particularly prone to the formation of an oxazolone.



Dissolution of phenaceturic acid (**1**) in hot ethyl acetate (10 mL per mmole) and addition of one equivalent of dicyclohexylcarbodiimide (DCC) leads to the quantitative formation of the 2-benzyl-5-(4*H*)-oxazolone (**2**) and

precipitation of the dicyclohexylurea. However, this oxazolone only reacts with phenol at 50 °C in a concentrated EtOAc solution to give the phenyl phenacetate in 60 % yield. Therefore we sought for a milder method compatible with fragile phenols. In the esterification of amino acids mediated by DCC, pyridine as solvent increases the reactivity of *ortho*-nitrophenol and reduces the amount of *N*-acylurea byproducts.⁶ Furthermore, Holmberg and Hansen have observed that a strong acid, such as *p*-toluenesulfonic acid (*p*-TSA), improves the yields of the esterification reaction.⁷ On the other hand, *N*-acylation of the acid **1** should give an imide which after activation could not cyclize.⁸ Some secondary amides have been efficiently *N*-*tert*-butoxycarbonylated by using di-*tert*-butyl dicarbonate and 4-dimethylaminopyridine (Boc₂O/DMAP).⁹

Alkylation of cesium phenacetate with benzyl bromide in DMF gave the benzyl phenacetate. Then, treatment with Boc₂O/DMAP and hydrogenolysis of the benzyl protecting group furnished the *N*-*tert*-butoxycarbonylphenaceturic acid (**4**) in 80 % overall yield. In the *tert*-butoxycarbonylation reaction, a small amount of a di-Boc derivative was isolated (see Experimental).

A comparative esterification of a series of phenols with phenaceturic acid (**1**) or its *N*-Boc derivative **4**, using the same DCC/*p*-TSA/pyridine conditions has been performed (Table 1). Substituted esters **5** are obtained in higher yields than esters **3**, particularly in the case of the acidic phenols (Y = NO₂ or CO₂Et). Moreover esters **5** are more stable than esters **3** and do not decompose on silica gel. Cleavage of the Boc protecting group from **5** with a slight excess of trifluoroacetic acid gives the aryl phenacetate **3** in quantitative yield, without chromatographic purification. On the whole, the indirect route, which needs the synthesis of the *tert*-butoxycarbonylated acid **4**, is valuable in the case of phenols possessing electron-withdrawing substituents.

Phenylacetyl glycine (**1**) was prepared following ref 4. The other reagents were obtained commercially and were used without purification. ¹H spectra were recorded on a Bruker AC 200E at 200 MHz and ¹³C spectra at 50 MHz with TMS as internal standard. TLC was performed on silica gel 60F-254 (Merck) and visualized with UV light. Column chromatography was carried out on silica gel 60 (70–230 mesh). Unless otherwise stated, the eluent used is the same for TLC and for column chromatography purification.

Compounds **3b–d**, **4** and **5a–d** gave C, H, N \pm 0.31 %.

Benzyl *N*-Phenylacetyl glycinate:

To a solution of *N*-phenylacetyl glycine (**1**) (4.83 g, 25 mmol) in MeOH (100 mL) and water (10 mL) was added a solution of CsCO₃ (4.1 g, 12.5 mmol) in water (20 mL). The mixture was evaporated and the residue was dried (P₂O₅) under vacuum. To this solid was added DMF (60 mL), then benzyl bromide (3.3 mL, 27.5 mmol). The suspension was stirred at r. t. for 24 h, then DMF was removed at 45 °C under vacuum. The residue was distributed between CH₂Cl₂

Table 1. Yields of Aryl Phenaceturates **3** and **5**.

Product	Yield ^a (%)	Yield ^b (%)
3a	58	71
3b	30 ^c	68
3c	31 ^c	—
3d	71	—
5a	78	79
5b	82	86
5c	86	—
5d	84	—

^a Yield of isolated product.^b Yield estimated by NMR.^c Phenaceturates of acidic phenols decompose on SiO₂.

and water. The organic phase was dried (Na₂SO₄) and evaporated. The crude product was purified by chromatography (CH₂Cl₂ followed by CH₂Cl₂/EtOAc, 95:5), affording 6.81 g (95% yield) of the desired product; R_f 0.22 (CH₂Cl₂/MeOH, 99:1); mp 92–93°C (EtOAc).

¹H NMR (CDCl₃): δ = 3.60 (s, 2 H, PhCH₂), 4.02 (d, *J* = 5.5 Hz, 2 H, NCH₂), 5.13 (s, 2 H, OCH₂Ph'), 6.86 (br, 1 H, NH), 7.21 and 7.26 (m, 10 H, Ph and Ph').

¹³C NMR (CDCl₃): δ = 41.2 (NCH₂), 43.0 (PhCH₂), 66.9 (CH₂OPh'), 127.1, 128.1, 128.3, 128.4, 128.7, 129.2, 134.4 and 135.0 (Ph and Ph'), 169.5 (COO), 171.1 (CON).

Anal. Calc. for C₁₇H₁₇NO₃ (283.31): C, 72.06; H, 6.05; N, 4.94. Found: C, 71.77; H, 6.05; N, 4.85.

Benzyl *N*-Boc-*N*-phenylacetylglucinate:

A solution of benzyl *N*-phenylacetylglucinate (0.68 g, 2.4 mmol), (Boc)₂O (0.628 g, 2.88 mmol) and DMAP (29.3 mg, 0.24 mmol) in CH₃CN (6 mL) was stirred at r.t. overnight. The solvent was evaporated and the residue purified by chromatography (pentane/EtOAc, 97:3 then 97:5), giving 820 mg (89% yield) of the title product, as an oil; R_f 0.4 (pentane/EtOAc, 9:1).

¹H NMR (CDCl₃): δ = 1.38 (s, 9 H, Boc), 4.28 (s, 2 H, PhCH₂), 4.49 (s, 2 H, NCH₂), 5.12 (s, 2 H, OCH₂Ph'), 7.23 and 7.30 (m, 10 H, Ph and Ph').

¹³C NMR (CDCl₃): δ = 27.6 (Boc), 43.9 (PhCH₂), 45.5 (NCH₂), 66.8 (CH₂OPh'), 83.9 (NCOOC), 126.7, 128.2, 128.3, 128.5, 129.5, 134.7 and 135.3 (Ph and Ph'), 151.9 (NCOO), 168.7 (COO), 173.7 (CON).

Anal. Calc. for C₂₂H₂₅NO₅ (383.43): C, 68.91; H, 6.57; N, 3.65. Found: C, 68.45; H, 6.44; N, 3.45.

A small amount, 40 mg (3.4% yield), of the di-Boc product: R_f 0.24 (pentane/EtOAc, 9:1) was also obtained as an oil.

¹H NMR (CDCl₃): δ = 1.39 (s, 9 H, Boc), 1.43 (s, 9 H, O-Boc), 4.52 (q, *J*_{AB} = 7.3 Hz, 2 H, NCH₂), 5.16 (s, 2 H, OCH₂Ph'), 5.62 (s, 1 H, PhCH=C), 7.31–7.36 (m, Ph and Ph').

¹³C NMR (CDCl₃): δ = 27.6 and 27.7 (2 × *t*-Bu), 45.5 (NCH₂), 66.8 (OCH₂Ph'), 80.6 (PhCH=C), 82.0 (OCOOC), 84.1 (NCOOC), 127.7, 128.2, 128.4, 128.5, 129.6, 134.1 and 135.3 (Ph and Ph'), 150.2 (NCOO), 168.4 (COO), 170.3 (OCOOC), 175.5 (=C(O)N).

MS (FAB): *m/z* = 490 (M + Li)⁺, 390 (M – Boc + H + Li)⁺, 290 (M – 2Boc + 2H + Li)⁺.

***N*-Boc-*N*-phenylacetylglucine (**4**):**

A mixture of benzyl *N*-Boc-*N*-phenylacetylglucinate (0.65 g, 1.69 mmol) and 10% Pd/C (40 mg) in MeOH (40 mL) was hydrogenated at 50 lb/in² pressure at r.t. for 2 h. The reaction mixture was then filtered and evaporated. The crude product was purified by chromatography (CH₂Cl₂ followed by CH₂Cl₂/MeOH, 95:5), giving 473 mg (95% yield) of the title product **4**; R_f 0.36 (CH₂Cl₂/MeOH, 95:5).

¹H NMR (CDCl₃): δ = 1.48 (s, 9 H, NBoc), 4.30 (s, 2 H, PhCH₂), 4.51 (s, 2 H, NCH₂), 7.25 and 7.34 (m, 5 H, Ph), 10.0 (br, 1 H, CO₂H).

¹³C NMR (CDCl₃): δ = 27.7 (Boc), 43.9 (PhCH₂), 45.2 (NCH₂), 84.3 (NCO₂C), 126.8, 128.3, 128.4, 129.5, and 134.5 (Ph), 151.8 (NCOO), 173.9 (CON), 175.0 (CO₂H).

Esterification Reactions; General Procedure:

To a mixture of a phenol and 1.5 equiv of acid **1** or **4** in anhyd. pyridine (1 mL/mmol) was added a catalytic amount of *p*-TsOH · H₂O (10 mg per mmol of phenol) and DCC (1.5 equiv). The resulting mixture was stirred at r.t. overnight, and then EtOAc and 10% HCl was added. The white precipitate (DCU) was filtered. The filtrate was separated and the organic phase was washed with water, dried (Na₂SO₄) and evaporated to give the crude product **3** or **5** which was purified by chromatography and crystallization.

Deprotection; General Procedure:

A solution of a *N*-Boc protected ester **5** in trifluoroacetic acid (4 equiv) was stirred at r.t. overnight and evaporated to remove the TFA. The obtained solid was dried over P₂O₅ and KOH under vacuum to give quantitatively the final product **3**.

3a: R_f 0.13 (CH₂Cl₂); mp 137–138°C (MeOH) (lit.² mp 132–133°C).

¹H NMR (CDCl₃): δ = 3.62 (s, 2 H, PhCH₂), 4.22 (d, *J* = 5.4 Hz, 2 H, NCH₂), 6.22 (br, 1 H, NH), 7.04 (d, *J*_{AB} = 7.6 Hz, 2-H, 3-H and 5-H), 7.18–7.39 (m, 7 H, 2-H, 6-H and Ph).

3b: R_f 0.12 (CH₂Cl₂); mp 142–143°C (MeOH).

¹H NMR (CDCl₃): δ = 3.62 (s, 2 H, PhCH₂), 4.22 (d, *J* = 5.6 Hz, 2 H, NCH₂), 5.93 (br, 1 H, NH), 7.17–7.36 (m, 7 H, 2-H, 6-H and Ph), 8.20 (d, *J*_{AB} = 8.9 Hz, 2 H, 2-H and 5-H).

3c: R_f 0.14 (CH₂Cl₂); mp 126–127°C (MeOH).

¹H NMR (CDCl₃): δ = 1.38 (t, *J* = 7.1 Hz, 3 H, OCH₂CH₃), 3.66 (s, 2 H, PhCH₂), 4.25 (d, *J* = 5.5 Hz, 2 H, NCH₂), 4.36 (q, *J* = 7.1 Hz, 2 H, OCH₂CH₃), 7.14 (d, *J*_{AB} = 8.7 Hz, 2 H, 2-H and 6-H), 7.28–7.39 (m, 5 H, Ph), 8.06 (d, *J*_{AB} = 8.7 Hz, 2 H, 3-H and 5-H).

3d: R_f 0.14 (CH₂Cl₂); mp 163–164°C (MeOH).

¹H NMR (acetone-*d*₆): δ = 2.49 (s, 3 H, SCH₃), 3.60 (s, 2 H, PhCH₂), 4.19 (d, *J* = 5.8 Hz, 2 H, NCH₂), 7.00 (d, *J*_{AB} = 8.7 Hz, 2 H, 3-H and 5-H); 7.21–7.32 (m, 7 H, 2-H, 6-H and Ph), 7.36 (br, 1 H, NH).

5a: R_f 0.50 (CH₂Cl₂); oil. ¹H NMR (CDCl₃): δ = 1.49 (s, 9 H, Boc), 4.32 (s, 2 H, PhCH₂), 4.70 (s, 2 H, NCH₂), 7.04–7.34 (m, 9 H, Ph and Ar).

5b: R_f 0.58 (CH₂Cl₂); oil.

¹H NMR (CDCl₃): δ = 1.52 (s, 9 H, Boc), 4.33 (s, 2 H, PhCH₂), 4.75 (s, 2 H, NCH₂), 7.24–7.32 (m, 7 H, 2-H, 6-H and Ph), 8.24 (d, *J*_{AB} = 9.0 Hz, 2 H, 3-H and 5-H).

5c: R_f 0.42 (CH₂Cl₂); oil.

¹H NMR (CDCl₃): δ = 1.38 (t, *J* = 7.1 Hz, 3 H, OCH₂CH₃), 1.51 (s, 9 H, Boc), 4.33 (s, 2 H, PhCH₂), 4.36 (q, *J* = 7.1 Hz, 2 H, OCH₂CH₃), 4.73 (s, 2 H, NCH₂), 7.16 (d, *J*_{AB} = 8.7 Hz, 2 H, 2-H and 6-H), 7.23–7.31 (m, 5 H, Ph), 8.07 (d, *J*_{5,6} = 8.7 Hz, 2 H, 3-H and 5-H).

5d: R_f 0.42 (CH₂Cl₂); oil.

¹H NMR (CDCl₃): δ = 1.50 (s, 9 H, Boc), 2.45 (s, 3 H, SCH₃), 4.32 (s, 2 H, PhCH₂), 4.70 (s, 2 H, NCH₂), 7.00 (d, *J*_{AB} = 8.7 Hz, 2 H, 3-H and 5-H), 7.22–7.30 (m, 7 H, 2-H, 6-H and Ph).

- (1) Xu, Y.; Pratt, R.F.; Cabaret, D.; Liu, J.; Wakselman, M., manuscript in preparation.
- (2) Kern, S.F.; Terril, P.M.; Mann, M.M.; Jones, R.G. *Science* **1950**, *112*, 787.

- (3) Simmons, B.D.L.; Frechette, M.; Ranz, R.J.; Chen, W.S. *Can. J. Pharm. Sci.* **1967**, *2*, 53.
- (4) Govardhan, C.P.; Pratt, R.F. *Biochemistry* **1987**, *26*, 3385.
- (5) De Jersey, J.; Willaden, P.; Zerner, B. *Biochemistry* **1969**, *8*, 1959.
- Williams, A. *J. Chem. Soc., Perkin Trans. 2* **1975**, 947.
- (6) Bodansky, M.; Kondo, M.; Yang Lin, C.; Sigler, G.F. *J. Org. Chem.* **1974**, *39*, 444.
- (7) Holmberg, K.; Hansen, B. *Acta Chem. Scand.* **1979**, *B33*, 410.
- (8) Gunnarsson, K.; Ragnarsson, U. *Acta Chem. Scand.* **1990**, *44*, 944.
- (9) Flynn, D.L.; Zelle, R.E.; Grieco, P.A. *J. Org. Chem.* **1983**, *48*, 2424.
- M. Wakselman *di-tert-butyl dicarbonate* In *Encyclopedia of Reagents for Organic Synthesis*; Paquette, L.A., Ed; Wiley: in press.